Locally Advanced Cervical Cancer: What is the Preferred Systemic Treatment?
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: LACC is approximately 74%
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The role of additional systemic chemotherapy or immunotherapy has been investigated in prospective randomized controlled trials, and recently published results suggest the benefit of alternative regimens. This review discusses the history of treatment with concurrent cisplatin-based CRT and examines data on consolidation chemotherapy, induction chemotherapy, and immunotherapy in LACC.
Cervical cancer remains the fourth most common malignancy among women globally and is a leading cause of cancer mortality.
APA
Flint ML, Byrne ME, Friedman CF (2025). Locally Advanced Cervical Cancer: What is the Preferred Systemic Treatment?. Journal of the National Comprehensive Cancer Network : JNCCN, 23(12). https://doi.org/10.6004/jnccn.2025.7123
MLA
Flint ML, et al.. "Locally Advanced Cervical Cancer: What is the Preferred Systemic Treatment?." Journal of the National Comprehensive Cancer Network : JNCCN, vol. 23, no. 12, 2025.
PMID
41671446 ↗
Abstract 한글 요약
Cervical cancer remains the fourth most common malignancy among women globally and is a leading cause of cancer mortality. For patients with locally advanced cervical cancer (LACC), the established standard of care is definitive treatment with concurrent cisplatin therapy and external-beam radiation therapy (chemoradiotherapy [CRT]) followed by brachytherapy. Although treatment with CRT is potentially curative, recent studies have shown the 5-year overall survival rate for patients with LACC is approximately 74%. The role of additional systemic chemotherapy or immunotherapy has been investigated in prospective randomized controlled trials, and recently published results suggest the benefit of alternative regimens. This review discusses the history of treatment with concurrent cisplatin-based CRT and examines data on consolidation chemotherapy, induction chemotherapy, and immunotherapy in LACC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.